Efficacy of newer agents in the glycaemic management of patients with type 2 diabetes
- 4 November 2019
- journal article
- editorial
- Published by Taylor & Francis Ltd in Current Medical Research and Opinion
- Vol. 36 (2), 209-211
- https://doi.org/10.1080/03007995.2019.1678344
Abstract
Efficacy of newer agents in the glycaemic management of patients with Type 2 Diabetes. Current Medical Research and Opinion. Accepted 7 October 2019.Keywords
This publication has 31 references indexed in Scilit:
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 DiabetesThe New England Journal of Medicine, 2015
- Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trialThe Lancet, 2014
- Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 studyThe Lancet Diabetes & Endocrinology, 2014
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes MellitusThe New England Journal of Medicine, 2013
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 DiabetesThe New England Journal of Medicine, 2013
- Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trialDiabetologia, 2013
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label studyThe Lancet, 2012
- Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 DiabetesEndocrine Reviews, 2011
- One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trialInternational Journal of Clinical Practice, 2011
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)The Lancet, 2009